Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+T and NK Cells-Reference-Cited by-同舟云学术

Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+T and NK Cells

Published:2014-11-26 Issue:1 Volume:194 Page:438-445
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Gao Xin,Wang Xuefeng,Yang Qianting,Zhao Xin,Wen Wen,Li Gang,Lu Junfeng,Qin Wenxin,Qi Yuan,Xie Fang,Jiang Jingting,Wu Changping,Zhang Xueguang,Chen Xinchun,Turnquist Heth,Zhu Yibei,Lu Binfeng

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference42 articles.

1. Cancer immunoediting: from immunosurveillance to tumor escape

2. Cancer Immunology

3. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 17: 4550–4557.

4. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

5. Nivolumab plus Ipilimumab in Advanced Melanoma

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-33/ST2 Signaling and its Correlation with Macrophage Heterogeneity and Clinicopathologic Features in Human Intrahepatic Cholangiocarcinoma;Current Cancer Drug Targets;2024-11

2. Interleukin-33 from oligodendrocytes sustains effector differentiation of tissue-resident CD8+ T cells and is a druggable target in CNS autoimmune disease;2024-07-13

3. BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells;Cellular & Molecular Immunology;2024-06-28

4. IL-33 and IL-33-derived DC-based tumor immunotherapy;Experimental & Molecular Medicine;2024-06-03

5. Unveiling the multifaceted antitumor effects of interleukin 33;Frontiers in Immunology;2024-05-31